Effects of three metabolites of propiverine on voltage-dependent L-type calcium currents in human atrial myocytes

European Journal of Pharmacology

Volumn 598, Issue 1-3, 2008, Pages 94-97

  Wuest, Melinda ^a   Christ, Torsten ^a   Hiller, Nicole ^a   Braeter, Manfred ^b   Ravens, Ursula ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

Human atrial myocyte; L type Ca2+ current; Propiverine and metabolite

Indexed keywords

2,2 DIPHENYL 2 HYDROXYACETIC ACID (1 METHYLPIPERID 4 YL) ESTER; 2,2 DIPHENYL 2 PROPOXYACETIC ACID (1 METHYLPIPERID 4 YL) ESTER; 2,2 DIPHENYL 2 PROPOXYACETIC ACID (PIPERID 4 YL) ESTER; CALCIUM CHANNEL L TYPE; DRUG METABOLITE; PROPIVERINE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DETRUSOR MUSCLE; HEART ATRIUM; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IC 50; PRIORITY JOURNAL;

BENZILATES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELL SEPARATION; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART ATRIA; HUMANS; MEMBRANE POTENTIALS; MYOCYTES, CARDIAC; NISOLDIPINE;

EID: 54049155617     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.08.035     Document Type: Article

References (18)

1. 2+-current by direct interaction with the Cav1.2 subunit. Naunyn-Schmiedeberg's Arch. Pharmacol. 370 (2004) 474-483
2. Christ T., Wettwer E., Wuest M., Braeter M., Donath F., Champeroux P., Richard S., and Ravens U. Electrophysiological profile of propiverine - relationship to cardiac risk. Naunyn-Schmiedeberg's Arch. Pharmacol. 376 (2008) 431-440
3. Haustein K.O., and Hüller G. On the pharmacokinetics and metabolism of propiverine in man. Eur. J. Drug. Metab. Pharmacokinet. 13 (1988) 81-90
4. Madersbacher H., and Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J. Urol. 19 (2001) 324-335
5. Maruyama S., Oki T., Otsuka A., Shinbo H., Ozono S., Kageyama S., Mikami Y., Araki I., Takeda M., Masuyama K., and Yamada S. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J. Urol. 175 (2006) 365-369
6. May K., Westphal K., Giessmann T., Wegner D., Adam U., Lerch M.M., Oertel R., Warzok R.W., Weitschies W., Braeter M., and Siegmund W. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms. J. Clin. Pharmacol. 48 (2008) 570-579
7. Schneider T., Fetscher C., Krege S., and Michel M.C. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J. Pharmacol. Exp. Ther. 309 (2004) 1148-1153
8. Siegmund W., Niguissie M., Talahun K., Aitenfissu H., Franke G., and Wengler A. Anticholinergic properties of propiverine and its metabolites. Pharmazie 45 (1990) 67-68
9. Siepmann M., Nokhodian A., Thümmler D., and Kirch W. Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur. J. Clin. Pharmacol. 54 (1998) 767-771
10. Tokuno H., Chowdhury J.U., and Tomita T. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 348 (1993) 659-662
11. Uchida S., Kurosawa S., Fujino Oki T., Kato Y., Nanri M., Yoshida K., and Yamada S. Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sci. 80 (2007) 2454-2460
12. Wada Y., Yoshida M., Kitani K., Kikukawa H., Ichinose A., Takahashi W., Gotoh S., Inadome A., Machida J., and Ueda S. Comparison of the effects of anticholinergic drugs on human isolated urinary bladder. Arch. Int. Pharmacodyn. 330 (1995) 76-79
13. v1.2 L-type calcium channel for urinary bladder function. FASEB J. 18 (2004) 1159-1161
14. Wuest M., Hecht J., Christ T., Braeter M., Schoeberl C., Hakenberg O.W., Wirth M.P., and Ravens U. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br. J. Pharmacol. 145 (2005) 608-619
15. Wuest M., Weiss A., Waelbroeck M., Braeter M., Kelly L.-U., Hakenberg O.W., and Ravens U. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn-Schmiedeberg's Arch. Pharmacol. 374 (2006) 87-97
16. 2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur. J. Pharmacol. 565 (2007) 180-189
17. Wuest M., Eichhorn B., Braeter M., Strugala G., Michel M.C., and Ravens U. Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Arch. 456 (2008) 349-358
18. 2+ transients in murine urinary bladder myocytes. J. Pharmacol. Exp. Ther. 324 (2008) 118-127